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Abstract Tobacco smoking has been inconsistently
associated with gallbladder disease risk. To clarify the
association we conducted a systematic review and meta-
analysis of cohort studies published on the subject. We
searched the PubMed and Embase databases for studies of
smoking and gallbladder disease up to January 9th 2015.
Prospective studies were included if they reported relative
risk estimates and 95 % confidence intervals of gallbladder
disease associated with current, former or ever smoking
and by number of cigarettes per day. Summary relative
risks were estimated by use of a random effects model. We
identified ten prospective studies including 59,530 gall-
bladder disease cases among 4,213,482 participants that
could be included in the meta-analysis. The summary RR
was 1.19 (95 % CI 1.12–1.28, I2 = 46.9 %, n = 6) for
current smokers, 1.10 (95 % CI 1.07–1.13, I2 = 0 %,
n = 6) for former smokers and 1.15 (95 % CI 1.13–1.18,
I2 = 0 %, n = 7) for ever smokers. In the dose–response
analysis the summary relative risk was 1.11 (95 % CI
1.08–1.14, I2 = 33 %, n = 3) per 10 cigarettes per day and
although there was indication of nonlinearity there was a
dose-dependent positive association with increasing num-
ber of cigarettes smoked per day. The current meta-analysis
provides evidence of an increased risk of gallbladder dis-
ease associated with tobacco smoking.
Keywords Tobacco smoking  Gallstones 
Cholelithiasis  Cholecystectomy  Gallbladder disease 
Cohort studies  Meta-analysis
Introduction
Gallbladder disease is a major cause of morbidity in the US
and in the Europe. The prevalence of asymptomatic gall-
bladder disease ranges between 10–30 % within these
populations [1], while symptomatic gallbladder disease is
less frequent and affects approximately 2 % of the popu-
lation [2]. Of digestive diseases that require hospitalization
gallbladder disease is the most frequent and costly; the
economic costs of hospital treatment of gallbladder disease
is over 5 billion US dollar per year [3, 4].
Tobacco smoking is believed to affect the hepatobiliary
system and has been associated with increased risk of liver
[5] and gallbladder cancer [6]. Studies of smoking in
relation to gallbladder disease and gallstones risk have,
however, been mixed. Several case–control and cross-
sectional studies did not find an association [7–11] or even
inverse associations [12], while a few did report increased
risk [13, 14], although not always significantly so. How-
ever, it is possible that such studies may have been affected
by recall bias, selection bias or temporal biases, thus it’s
difficult to draw conclusions based on these study designs.
Prospective studies, which are less prone to such biases,
have also been inconsistent with some studies showing no
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significant association [15, 16], while some larger studies
did report a moderate increase in risk associated with
tobacco smoking [17–24], and some [17, 20, 21] of these
suggested a dose–response relationship with increasing
number of cigarettes smoked per day. We conducted a
systematic review and meta-analysis of cohort studies on
the association between smoking and gallbladder disease
with the aim of clarifying whether there is an association,
the strength of any potential association and if there is a
dose–response relationship between smoking and gall-
bladder disease.
Methods
Search strategy and inclusion criteria
We developed a systematic review protocol for the project.
Pubmed and Embase databases were searched up to Jan-
uary 9th 2015 for eligible studies. As part of a larger
project on risk factors for gallbladder disease we used wide
search terms PubMed search: (body mass index OR BMI
OR overweight OR obesity OR anthropometry OR fatness
OR body fatness OR abdominal fatness OR abdominal
obesity OR waist circumference OR waist-to-hip ratio OR
physical activity OR exercise OR sports OR walking OR
biking OR running OR fitness OR exercise test OR inac-
tivity OR diabetes OR smoking OR tobacco OR risk factor
OR risk factors) AND (gallstones OR gallbladder disease
OR cholelithiasis OR cholecystectomy OR cholecystitis).
We followed standard criteria for conducting and reporting
meta-analyses [25]. In addition, we searched the reference
lists of the identified publications for further studies. One
reviewer (DA) conducted the initial screening of all the
references and two reviewers (DA, LJV) conducted the
screening of the potentially eligible studies. Any dis-
agreements were resolved by discussion between the
authors.
Study selection
We included published prospective studies that investi-
gated the association between smoking and the risk of
gallbladder disease, gallstones, or cholecystectomies.
Adjusted estimates of the relative risk had to be available
with the 95 % CIs in the publication. For the dose–re-
sponse analysis a quantitative measure of the smoking level
had to be provided. We identified ten relevant prospective
studies that could be included in the analysis [15–24]. A
list of the excluded studies and the reason for exclusion is
provided in Supplementary Table 1.
Data extraction
The following data were extracted from each study: The
first author’s last name, publication year, country where the
study was conducted, study period, sample size, sex,
number of cases, smoking type, cigarettes per day, relative
risks and 95 % confidence intervals for the highest versus
the lowest level of smoking and variables adjusted for in
the analysis. One reviewer extracted the data (DA) and
they were checked for accuracy by a second reviewer
(LJV). Any disagreements were resolved by discussion.
Statistical methods
We calculated summary relative risks for the highest versus
the lowest level of smoking using the random-effects
model by DerSimonian and Laird [26] which takes into
account both within and between study variation (hetero-
geneity). The average of the natural logarithm of the rel-
ative risks was estimated and the relative risk from each
study was weighted by the inverse of its variance.
To investigate whether the number of cigarettes
smoked per day was associated with gallbladder disease
we used the method described by Greenland and Long-
necker [27] to conduct dose–response analysis by
12747 records identified in total:
7799 records identified in PubMed
4948 records identified in Embase
61 given detailed assessment
12686 excluded based on title 
or abstract
10 prospective studies 
included
51 publications excluded:
26 cross-sectional studies
10 case-control studies
4 comment, letter, 
2 case only studies
2 unadjusted risk estimates
1 no risk estimates
1 not relevant outcome
1 pregnant women
1 review
1 abstract
1 duplicate
1 combined never/former 
smokers in reference category
Fig. 1 Flow-chart of study selection
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computing study-specific slopes (linear trends) and 95 %
confidence intervals from the natural log of the relative
risks and confidence intervals across categories of
cigarettes per day. The method requires that the distri-
bution of cases and person-years or non-cases and the
relative risks with the variance estimates for at least
three quantitative exposure categories are known. For
studies that did not provide this information, we esti-
mated the distribution of cases and person-years or non-
cases based on a method previously described [28].
Studies that did not quantify the number of cigarettes
smoked per day were excluded from the dose–response
analysis. We assessed a potential nonlinear dose–re-
sponse relationship between smoking and gallbladder
disease using fractional polynomial models. We deter-
mined the best fitting second order fractional polynomial
regression model, defined as the one with the lowest
deviance. A likelihood ratio test was used to assess the
A
B
Former smokers versus never smokers and gallbladder disease
Current smokers versus never smokers and gallbladder disease
 Relative Risk
 .5  .75  1  1.5  2
 Study
 Relative Risk
 (95% CI)
 Liu, 2009   1.22 ( 1.18, 1.26)
 Gonzalez-Perez, 2007   1.05 ( 0.94, 1.19)
 Sahi, 1998   1.47 ( 1.13, 1.92)
 Grodstein, 1994   1.30 ( 1.00, 1.70)
 Kato, 1992   1.30 ( 1.00, 1.60)
 Stampfer, 1992   1.16 ( 1.07, 1.27)
 Overall   1.19 ( 1.12, 1.28)
 Relative Risk
 .5  .75  1  1.5  2
 Study
 Relative Risk
 (95% CI)
 Liu, 2009   1.10 ( 1.06, 1.13)
 Gonzalez-Perez, 2007   1.18 ( 0.99, 1.41)
 Sahi, 1998   1.28 ( 0.89, 1.85)
 Grodstein, 1994   1.10 ( 0.80, 1.40)
 Kato, 1992   1.10 ( 0.90, 1.50)
 Stampfer, 1992   1.06 ( 0.96, 1.17)
 Overall   1.10 ( 1.07, 1.13)
Fig. 2 Current smokers (a) and
former smokers (b) versus never
smokers and gallbladder disease
Tobacco smoking and the risk of gallbladder disease
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difference between the nonlinear and linear models to
test for nonlinearity [29].
Heterogeneity between studies was evaluated using Q
and I2 statistics [30]. All statistical tests were two-sided and
p\ 0.05 considered statistically significant. I2-values of
25, 50 and 75 % indicates low, moderate and high
heterogeneity, respectively [31]. We conducted main
analyses (all studies combined) and stratified by study
characteristics such as sample size, number of cases, geo-
graphic location, study quality score and by adjustment for
confounding factors. Study quality was assessed using the
Newcastle-Ottawa scale which ranks the studies on a scale
from 0 to 9 based on the selection of the study population,
comparability between cases and non-cases and the
assessment of the outcome [32].
Publication bias was assessed using Egger’s test [33]
and Begg-Mazumdar’s test [34] and with funnel plots, and
p\ 0.10 was considered to indicate possible publication
bias as the tests have low power when the number of
studies is low. The statistical analyses were conducted
using the software package Stata, version 9.0 software
(StataCorp, Texas, US).
Results
Out of a total of 12,747 records identified by the searches,
we identified 10 prospective studies [15–24] involving a
total of 61,071 cases among 4,344,553 participants that
could be included in the analyses of smoking and gall-
bladder disease (Fig. 1, Table 1). Five of the studies were
from North-America, four were from Europe and one was
from Asia (Table 1).
Smoking status
Six cohort studies [16–21] were included in the analysis of
current smoking and gallbladder disease and included
30,533 cases among 1,513,524 participants. The summary
RR was 1.19 (95 % CI 1.12–1.28, I2 = 46.9 %, pheterogene-
ity = 0.09) (Fig. 2a). Six cohort studies [16–21] were
included in the analysis of former smoking and gallbladder
disease (30,533 cases and 1,513,524 participants) and the
summary RR was 1.10 (95 % CI 1.07–1.13, I2 = 0 %,
pheterogeneity = 0.88) (Fig. 2b). Seven cohort studies [16–21,
24] were included in the analysis of ever smoking and gall-
bladder disease (31,669 cases and 1,525,506 participants)
and the summary RR was 1.15 (95 % CI 1.13–1.18,
I2 = 0 %, pheterogeneity = 0.43) (Fig. 3). Three cohort stud-
ies [15, 22, 23] with 28,278 cases and 2768976 participants,
where the smoking status or the reference category was not
clearly defined, were analyzed separately and gave a sum-
mary RR of 1.70 (95 % CI 1.09–2.67, I2 = 97 %, phetero-
geneity\ 0.0001) (Supplementary Figure 1). There was no
evidence of publication bias in the analysis of current
smokers, p = 0.98 and p = 0.99 with Egger’s test and with
Begg’s test respectively, former smokers, p = 0.46 and
p = 0.71, or ever smokers, p = 0.58 and p = 0.37, respec-
tively, although there was possibly slight asymmetry in the
funnel plots (Supplementary Figures 2-4). However, this
was driven by one or two outlying studies which did not
affect the overall summary estimates.
 Relative Risk
 .5  .75  1  1.5  2
 Study
 Relative Risk
 (95% CI)
 Liu, 2009   1.16 ( 1.13, 1.19)
 Gonzalez-Perez, 2007   1.09 ( 0.99, 1.20)
 Yamada, 2005   1.19 ( 1.02, 1.40)
 Sahi, 1998   1.40 ( 1.13, 1.74)
 Grodstein, 1994   1.20 ( 0.99, 1.46)
 Kato, 1992   1.20 ( 1.01, 1.43)
 Stampfer, 1992   1.12 ( 1.05, 1.19)
 Overall   1.15 ( 1.13, 1.18)
Fig. 3 Ever smokers versus
never smokers and gallbladder
disease
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Dose–response analyses
Three cohort studies [17, 20, 21] were included in the
dose–response analysis of cigarettes per day and gallblad-
der disease risk. The summary relative risk was 1.11 (95 %
CI 1.08–1.14, I2 = 33 %, pheterogeneity = 0.23) per 10
cigarettes per day (Fig. 4a). There was some suggestion of
a nonlinear association, pnonlinearity\ 0.0001, with a
slightly steeper increase in the risk from low levels, but the
association appeared to be linear from about 5 cigarettes
per day (Fig. 4b).
Subgroup and sensitivity analyses and cumulative
meta-analyses
In subgroup analyses there were positive associations in
most strata, defined by study design, gender, outcometype,
geographic location, number of cases, study quality and
adjustment for confounding factors (Table 2). With meta-
regression analyses there was little evidence that the results
differed between these subgroups (Table 2). When we
conducted sensitivity analyses removing one study at a
time, the size of the summary estimates were very similar
A
B Cigarette smoking and gallbladder disease, nonlinear dose-response analysis
 Relative Risk
 .75  1  1.5
 Study
 Relative Risk
 (95% CI)
 Liu, 2009   1.12 ( 1.10, 1.15)
 Sahi, 1998   1.12 ( 0.99, 1.27)
 Stampfer, 1992   1.08 ( 1.04, 1.13)
 Overall   1.11 ( 1.08, 1.14)
1
1.25
1.5
1.75
2
RR
0 10 20 30 40
Cigarettes per day
Best fitting fractional polynomial
95% confidence interval
Cigarette smoking and gallbladder disease, linear dose-response analysis, 
per 10 cigarettes per day
Fig. 4 Cigarette smoking and
gallbladder disease, linear and
nonlinear dose–response
analyses
Tobacco smoking and the risk of gallbladder disease
123
T
a
b
le
2
S
u
b
g
ro
u
p
an
al
y
se
s
o
f
sm
o
k
in
g
an
d
g
al
lb
la
d
d
er
d
is
ea
se
C
u
rr
en
t
sm
o
k
in
g
F
o
rm
er
sm
o
k
in
g
E
v
er
sm
o
k
in
g
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
h2
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
hb
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
hb
A
ll
st
u
d
ie
s
6
1
.1
9
(1
.1
2
–
1
.2
8
)
4
6
.9
0
.0
9
6
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.8
8
7
1
.1
5
(1
.1
3
–
1
.1
8
)
0
0
.4
3
F
o
ll
o
w
-u
p
\
1
0
y
ea
rs
4
1
.1
7
(1
.0
9
–
1
.2
6
)
5
6
.1
0
.0
8
0
.2
0
4
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.7
7
0
.6
6
4
1
.1
5
(1
.1
2
–
1
.1
8
)
0
0
.4
8
0
.2
2
C
1
0
y
ea
rs
2
1
.3
7
(1
.1
5
–
1
.6
4
)
0
0
.5
0
2
1
.1
6
(0
.9
4
–
1
.4
3
)
0
0
.5
1
3
1
.2
4
(1
.1
2
–
1
.3
7
)
0
0
.4
5
G
en
d
er
M
en
2
1
.3
7
(1
.1
5
–
1
.6
4
)
0
0
.5
0
0
.0
5
/
0
.1
8
d
2
1
.1
6
(0
.9
4
–
1
.4
3
)
0
0
.5
1
0
.7
8
/
0
.6
6
d
2
1
.2
8
(1
.1
0
–
1
.4
8
)
1
5
.9
0
.2
8
0
.2
1
/
0
.2
5
d
W
o
m
en
3
1
.2
1
(1
.1
8
–
1
.2
5
)
0
0
.4
9
3
1
.1
0
(1
.0
6
–
1
.1
3
)
0
0
.7
8
3
1
.1
5
(1
.1
3
–
1
.1
8
)
0
0
.5
5
M
en
an
d
w
o
m
en
1
1
.0
5
(0
.9
4
–
1
.1
9
)
1
1
.1
8
(0
.9
9
–
1
.4
1
)
2
1
.1
2
(1
.0
3
–
1
.2
1
)
0
0
.3
5
S
tu
d
y
d
es
ig
n
C
o
h
o
rt
5
1
.2
2
(1
.1
8
–
1
.2
5
)
0
0
.4
5
0
.0
8
5
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.8
8
0
.4
7
6
1
.1
6
(1
.1
3
–
1
.1
9
)
0
0
.4
8
0
.2
8
N
es
te
d
ca
se
–
co
n
tr
o
l
st
u
d
y
1
1
.0
5
(0
.9
4
–
1
.1
9
)
1
1
.1
8
(0
.9
9
–
1
.4
1
)
1
1
.0
9
(0
.9
9
–
1
.2
0
)
O
u
tc
o
m
et
y
p
e
G
al
lb
la
d
d
er
d
is
ea
se
5
1
.1
9
(1
.1
0
–
1
.2
8
)
5
6
.1
0
.0
6
0
.5
2
5
1
.2
1
(1
.1
8
–
1
.2
5
)
0
0
.4
3
0
.0
5
5
1
.1
5
(1
.1
0
–
1
.2
0
)
2
9
.3
0
.2
3
0
.6
5
G
al
ls
to
n
es
2
1
.1
6
(1
.0
1
–
1
.3
3
)
1
.0
0
.3
2
2
1
.0
9
(0
.9
3
–
1
.2
9
)
0
0
.9
6
3
1
.1
5
(1
.0
5
–
1
.2
5
)
0
0
.6
6
C
h
o
le
cy
st
ec
to
m
y
1
1
.2
7
(1
.1
5
–
1
.3
9
)
1
1
.0
6
(0
.9
4
–
1
.1
8
)
1
1
.1
8
(1
.0
9
–
1
.2
7
)
G
eo
g
ra
p
h
ic
lo
ca
ti
o
n
E
u
ro
p
e
2
1
.1
4
(0
.9
9
–
1
.3
2
)
8
2
.7
0
.0
2
0
.3
8
2
1
.1
0
(1
.0
7
–
1
.1
4
)
0
0
.4
4
0
.6
7
2
1
.1
4
(1
.0
9
–
1
.2
0
)
3
3
.3
0
.2
2
0
.6
3
A
m
er
ic
a
4
1
.2
3
(1
.1
2
–
1
.3
6
)
1
7
.4
0
.3
0
4
1
.0
8
(0
.9
9
–
1
.1
7
)
0
0
.8
0
4
1
.1
8
(1
.0
8
–
1
.2
8
)
3
0
.1
0
.2
3
A
si
a
0
0
1
1
.1
9
(1
.0
2
–
1
.4
0
)
N
u
m
b
er
o
f
ca
se
s
C
as
es
\
1
0
0
0
3
1
.3
5
(1
.1
7
–
1
.5
6
)
0
0
.7
5
0
.1
7
3
1
.1
4
(0
.9
6
–
1
.3
4
)
0
0
.7
7
0
.7
2
3
1
.2
5
(1
.1
2
–
1
.4
0
)
0
0
.4
9
0
.2
1
C
as
es
C
1
0
0
0
3
1
.1
6
(1
.0
7
–
1
.2
5
)
6
9
.2
0
.0
4
3
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.5
7
4
1
.1
5
(1
.1
2
–
1
.1
8
)
0
0
.4
8
S
tu
d
y
q
u
al
it
y
0
–
3
st
ar
s
0
.5
5
0
0
.6
5
0
.8
3
4
–
6
st
ar
s
3
1
.2
4
(1
.0
8
–
1
.4
3
)
3
7
.4
0
.2
0
3
1
.0
8
(0
.9
8
–
1
.1
8
)
0
0
.6
1
4
1
.1
8
(1
.0
8
–
1
.2
8
)
2
9
.2
0
.2
4
7
–
9
st
ar
s
3
1
.1
7
(1
.0
5
–
1
.3
1
)
6
7
.5
0
.0
5
3
1
.1
0
(1
.0
7
–
1
.1
4
)
0
0
.7
5
3
1
.1
6
(1
.1
3
–
1
.1
8
)
0
0
.4
3
A
d
ju
st
m
en
t
fo
r
co
n
fo
u
n
d
in
g
fa
ct
o
rs
c
A
g
e
Y
es
6
1
.1
9
(1
.1
2
–
1
.2
8
)
4
6
.9
0
.0
9
N
C
6
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.8
8
N
C
7
1
.1
5
(1
.1
3
–
1
.1
8
)
0
0
.4
3
N
C
N
o
0
0
0
A
lc
o
h
o
l
Y
es
4
1
.1
7
(1
.0
9
–
1
.2
6
)
5
6
.1
0
.0
8
0
.2
0
3
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.7
7
0
.6
6
5
1
.1
5
(1
.1
3
–
1
.1
8
)
0
0
.6
2
0
.2
0
D. Aune et al.
123
T
a
b
le
2
co
n
ti
n
u
ed
C
u
rr
en
t
sm
o
k
in
g
F
o
rm
er
sm
o
k
in
g
E
v
er
sm
o
k
in
g
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
h2
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
hb
n
R
el
at
iv
e
ri
sk
(9
5
%
C
I)
I2 (%
)
P
ha
P
hb
N
o
2
1
.3
7
(1
.1
5
–
1
.6
4
)
0
0
.5
0
2
1
.1
6
(0
.9
4
–
1
.4
3
)
0
0
.5
1
2
1
.2
8
(1
.1
0
–
1
.4
8
)
1
5
.9
0
.2
8
B
M
I
Y
es
5
1
.1
9
(1
.1
0
–
1
.2
8
)
5
5
.6
0
.0
6
0
.5
9
5
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.7
7
0
.9
9
5
1
.1
5
(1
.1
0
–
1
.2
0
)
2
8
.8
0
.2
3
0
.6
1
N
o
1
1
.3
0
(1
.0
0
–
1
.6
0
)
1
1
.1
0
(0
.9
0
–
1
.5
0
)
2
1
.1
9
(1
.0
6
–
1
.3
4
)
0
0
.9
4
W
ei
g
h
t
ch
an
g
e
o
r
B
M
I
ch
an
g
e
Y
es
3
1
.2
4
(1
.0
8
–
1
.4
3
)
3
7
.4
0
.2
0
0
.5
5
3
1
.0
8
(0
.9
8
–
1
.1
8
)
0
0
.6
1
0
.6
5
3
1
.1
9
(1
.0
6
–
1
.3
5
)
5
0
.4
0
.1
3
0
.8
3
N
o
3
1
.1
7
(1
.0
5
–
1
.3
1
)
6
7
.5
0
.0
5
3
1
.1
0
(1
.0
7
–
1
.1
4
)
0
0
.7
5
4
1
.1
6
(1
.1
3
–
1
.1
9
)
0
0
.6
1
H
o
rm
o
n
e
re
p
la
ce
m
en
t
th
er
ap
y
Y
es
2
1
.1
7
(1
.0
8
–
1
.2
7
)
0
0
.4
2
0
.7
4
2
1
.0
6
(0
.9
7
–
1
.1
7
)
0
0
.8
1
0
.5
6
2
1
.1
3
(1
.0
6
–
1
.2
0
)
0
0
.5
1
0
.5
0
N
o
2
1
.1
4
(0
.9
9
–
1
.3
2
)
8
2
.7
0
.0
2
2
1
.1
0
(1
.0
7
–
1
.1
4
)
0
0
.4
4
3
1
.1
6
(1
.1
3
–
1
.1
8
)
0
0
.4
4
O
ra
l
co
n
tr
ac
ep
ti
v
e
u
se
Y
es
1
1
.3
0
(1
.0
0
–
1
.7
0
)
0
.5
4
1
1
.1
0
(0
.8
0
–
1
.4
0
)
0
.9
9
1
1
.2
0
(0
.9
9
–
1
.4
6
)
0
.6
9
N
o
3
1
.1
6
(1
.0
7
–
1
.2
5
)
6
9
.2
0
.0
4
3
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.5
7
4
1
.1
5
(1
.1
2
–
1
.1
8
)
0
0
.4
8
P
ar
it
y
Y
es
2
1
.1
7
(1
.0
8
–
1
.2
7
)
0
0
.4
2
0
.7
4
2
1
.0
6
(0
.9
7
–
1
.1
7
)
0
0
.8
1
0
.5
6
2
1
.1
3
(1
.0
6
–
1
.2
0
)
0
0
.5
1
0
.5
0
N
o
2
1
.1
4
(0
.9
9
–
1
.3
2
)
8
2
.7
0
.0
2
2
1
.1
0
(1
.0
7
–
1
.1
4
)
0
0
.4
4
3
1
.1
6
(1
.1
3
–
1
.1
8
)
0
0
.4
4
P
h
y
si
ca
l
ac
ti
v
it
y
Y
es
1
1
.4
7
(1
.1
3
–
1
.9
2
)
0
.2
1
1
1
.2
8
(0
.8
9
–
1
.8
5
)
0
.4
6
1
1
.4
0
(1
.1
3
–
1
.7
4
)
0
.1
4
N
o
5
1
.1
8
(1
.1
1
–
1
.2
6
)
4
4
.9
0
.1
2
5
1
.1
0
(1
.0
7
–
1
.1
3
)
0
0
.8
9
6
1
.1
5
(1
.1
3
–
1
.1
8
)
0
0
.7
2
n
d
en
o
te
s
th
e
n
u
m
b
er
o
f
st
u
d
ie
s
a
P
fo
r
h
et
er
o
g
en
ei
ty
w
it
h
in
ea
ch
su
b
g
ro
u
p
b
P
fo
r
h
et
er
o
g
en
ei
ty
b
et
w
ee
n
su
b
g
ro
u
p
s
w
it
h
m
et
a-
re
g
re
ss
io
n
an
al
y
si
s
c
N
u
m
b
er
o
f
st
u
d
ie
s
m
ay
n
o
t
ad
d
u
p
to
th
e
to
ta
l
b
ec
au
se
so
m
e
st
u
d
ie
s
d
id
n
o
t
re
p
o
rt
th
e
in
fo
rm
at
io
n
o
r
th
e
su
b
g
ro
u
p
an
al
y
si
s
m
ay
n
o
t
ap
p
ly
to
so
m
e
st
u
d
ie
s
(e
.g
.
su
b
g
ro
u
p
an
al
y
se
s
o
f
H
R
T
,
O
C
u
se
an
d
p
ar
it
y
ar
e
re
st
ri
ct
ed
to
st
u
d
ie
s
in
cl
u
d
in
g
w
o
m
en
)
d
P
fo
r
h
et
er
o
g
en
ei
ty
b
et
w
ee
n
m
en
an
d
w
o
m
en
(e
x
cl
u
d
in
g
st
u
d
ie
s
w
it
h
b
o
th
g
en
d
er
s)
Tobacco smoking and the risk of gallbladder disease
123
(Supplementary Figures 5-7). In cumulative meta-analyses,
there was little change in the size of the summary RRs over
time (Supplementary Figures 8-10), although for former
smoking the association became significant in 2007, while
for current and ever smoking the associations were sig-
nificant from the first studies published in 1992.
Discussion
To our knowledge this is the first meta-analysis of obser-
vational studies of smoking and risk of gallbladder disease
and our results confirm a 19 % increased relative risk
among current smokers, with a dose–response relationship
of increasing risk with increasing number of cigarettes
smoked per day. In addition, a 10 and 15 % increase in the
relative risk was observed for former and ever smokers as
well.
Little is known about the biological mechanisms that
could explain the adverse effect of smoking on risk of
gallbladder disease. Smoking has been shown to increase
the risk of type 2 diabetes [35] which is a risk factor for
gallbladder disease [36]. Cigarette smoking has also been
associated with increased risk of gallbladder cancer [6],
although the exact mechanism is not known. In addition,
smoking may increase gallbladder disease risk by reducing
plasma high density lipoprotein cholesterol concentrations
[37] as higher levels of HDL cholesterol are associated
with lower gallbladder disease risk [38]. Tobacco smoke
contains several dozens of toxic chemicals that may have
detrimental effects on the gallbladder by as yet unidentified
mechanisms. Further studies are needed to clarify the
mechanism(s) that may explain the increased risk of gall-
bladder disease among smokers.
The present systematic review and meta-analysis has
some limitations that need to be discussed. The number of
studies included was moderate and some studies could not
be included in the dose–response analysis because only
smoking status and not results for number of cigarettes per
day were reported. Further studies should aim to clarify the
dose–response relationship between number of cigarettes
per day, duration of smoking, and time since quitting
smoking in relation to gallbladder disease risk and report
sufficient details to be included in future updated dose–
response analyses. Many of the included studies adjusted
for important confounding factors and the results persisted
in subgroup analyses by whether the studies adjusted for
body mass index, weight change, alcohol, hormone
replacement therapy use and parity, although there were
few studies in some of these subgroup analyses. Publica-
tion bias is a possibility, but we did not find evidence of
such bias with the statistical tests used or by inspection of
the funnel plots, although the number of studies was
moderate. Strengths of the present meta-analysis include
the detailed dose–response, subgroup and sensitivity anal-
yses, and the large sample size providing a robust estimate
of the association between smoking and risk of gallbladder
disease.
In conclusion, the results from this systematic review
and meta-analysis provide further evidence that smoking
increases the risk of developing gallbladder disease. Con-
sidering the relatively few modifiable risk factors that have
been established for gallbladder disease as well as the
many other adverse effects of smoking, further efforts to
reduce the prevalence of smoking are needed. Any further
studies should report more detailed results by intensity and
duration of smoking and clarify the impact of smoking
cessation on gallbladder disease risk.
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